Our achievements. Our accomplishments. Our impact.



  • Catalyzing New Organizations

    The Stem Cell Network was critical for strategically identifying structural gaps in the Canadian stem cell research landscape and bringing together diverse stakeholder groups to seize those opportunities through the incubation and launch of new organizations.

    READ STORY

  • Public Engagement

    The Stem Cell Network has elevated the level of public discourse and understanding about stem cells in Canada by engaging Canadians in artistic, accessible and innovative explorations of emerging issues in the field and by becoming an active and respected presence online.

    READ STORY

  • Commercialization

    The Stem Cell Network’s catalysis of commercialization of stem cell research has led to 399 patent applications, 60 issued patents, 43 licenses granted, the growth or launch of 11 start-up biotechnology companies and the establishment of a new Centre for the Commercialization of Regenerative Medicine (CCRM) to develop a strong industry presence in several emerging technology areas likely to be crucial to the future delivery of stem cell-based therapies.

    READ STORY

  • Till & McCulloch Meetings

    The Stem Cell Network’s Annual General Meeting, which metamorphosed into the Till & McCulloch Meetings, is a one-of-a-kind venue for trainees and young scientists to network and gain experience in the competitive field of regenerative medicine.

    READ STORY

  • Stem Cell Plasticity

    Adult stem cells offer great potential as tools or targets of new treatments, and the Stem Cell Network launched a multidisciplinary project early in its mandate in order to discover more about the nature of these mysterious cells.

    READ STORY

  • Clinical Trials

    When the Stem Cell Network was first funded, its leadership considered that catalyzing a single clinical trial during its 14-year mandate would have been a success. Instead, the Network’s research investments have led to 12 clinical trials on various diseases, with even more in the development pipeline.

    READ STORY